Welcome to our dedicated page for Sensus Healthcare news (Ticker: SRTS), a resource for investors and traders seeking the latest updates and insights on Sensus Healthcare stock.
Sensus Healthcare, Inc. reports developments tied to its medical-device business for superficial radiotherapy treatments for oncological and non-oncological skin conditions. The company’s updates center on SRT and IG-SRT technology, including systems used in the treatment of non-melanoma skin cancer and keloids, as well as products and services that support dermatology and radiation-oncology practices.
Recurring news topics include quarterly results, reimbursement and CPT coding for superficial radiotherapy, customer acquisition programs, financing options through Sensus Healthcare Financial Services, installed-base software such as Sensus Link, Fair Deal Agreement activity, international customer development, and commercial or legal matters related to product sales and deployments.
Sensus Healthcare (Nasdaq: SRTS) has sold 10 Transdermal Infusion Systems™ to Hair Enhancement Centers (HEC) in Texas, aimed at non-invasive hair health treatments. The first two systems will be delivered in Q3 2022, followed by the rest in Q4. This system enables painless delivery of U.SK Under Skin's Skin Savers Hair™ serum deep into hair follicles, enhancing patient satisfaction and treatment results. HEC has rapidly expanded from 2 to 9 clinics in 2022, providing hair loss treatments to millions of affected Americans.
Sensus Healthcare, Inc. (Nasdaq: SRTS) will hold a conference call on August 4, 2022, at 4:30 p.m. ET to discuss its second-quarter 2022 financial results. The management will also provide a business update and details on recent and upcoming milestones. The call can be accessed via phone or live webcast. Following the call, a replay will be available until September 3, 2022. Sensus specializes in non-invasive treatments for oncological and non-oncological conditions, featuring proprietary low-energy X-ray technology known as superficial radiation therapy.
Sensus Healthcare, Inc. (Nasdaq: SRTS) has expanded its partnership with Colorado State University (CSU) by supplying a second SRT-100™ system for the study of superficial radiation therapy (SRT) in horses. This initiative takes place at CSU's Johnson Family Equine Hospital, aiming to investigate ophthalmic indications. With SRT showing promising results in earlier studies on other animals, the potential market for veterinary applications is significant, considering there are around 30,000 veterinary practices in the U.S. The CSU team hopes to publish their findings next year.
Summary not available.
On May 18, 2022, Sensus Healthcare (Nasdaq: SRTS) announced its participation in the H.C. Wainwright Global Investment Conference, scheduled for May 23-26, 2022. The company will present on May 25 at 9:30 a.m. Eastern time, with the presentation available live and archived on its website. Additionally, Sensus management, including President Michael Sardano and CFO Javier Rampolla, will hold one-on-one meetings with investors during the conference. Sensus specializes in non-invasive treatments for oncological and non-oncological conditions, utilizing proprietary low-energy X-ray technology.
Sensus Healthcare (SRTS) reported first quarter 2022 revenues of $10.3 million, a 237% increase compared to the previous year. Net income surged to $16.1 million, or $0.97 per diluted share, thanks to a $12.8 million gain from asset sales. The company exited the quarter with $32.8 million in cash. Adjusted EBITDA improved to $16.9 million, up from a loss of $0.8 million year-on-year. Sensus affirms expectations for continued growth and profitability in Q2 and the full year.
Sensus Healthcare, Inc. (Nasdaq: SRTS) has announced a conference call scheduled for May 5, 2022, at 4:30 p.m. Eastern time to discuss its financial results for Q1 2022. The call will also include a business update covering recent and upcoming milestones. Investors can access the call via dial-in numbers or through a live webcast on the company's website. Sensus Healthcare specializes in non-invasive treatments for oncological and non-oncological conditions, utilizing low-energy X-ray technology for various medical applications.
Sensus Healthcare (Nasdaq: SRTS) recently announced successful treatments using its SRT-100 system, demonstrating its capability in veterinary oncology. A mata mata turtle at Denver Zoo was treated for squamous cell carcinoma, showing no signs of the lesion three months post-therapy. This follows earlier treatments on various animals at Colorado State University, expanding the application of SRT in veterinary medicine. The ongoing partnership with CSU aims to develop protocols and clinical data, highlighting potential growth in a new market segment.
Sensus Healthcare (Nasdaq: SRTS), a medical device company, is set to present at two investment conferences in March 2022. The 34th Annual ROTH Conference will be held from March 13-15, with a key ‘Fireside Chat’ on March 15 at 9:30 a.m. PT. Investors can access the chat and a pre-recorded presentation on the company's website. Additionally, Sensus will participate in the Maxim 2022 Virtual Growth Conference on March 28-29, joining an Aesthetic Device Industry Panel on March 28 from 1:00 p.m. to 2:30 p.m. ET.
Sensus Healthcare, Inc. (Nasdaq: SRTS) announced a share buyback program authorizing the purchase of up to $3,000,000 of its common stock. CEO Joe Sardano expressed optimism about the company's future and stated that the buyback is a strategy to enhance shareholder value. The program, which has no time limit, allows for purchases through various methods and is subject to management's discretion based on financial assessments and market conditions. Sensus specializes in non-invasive medical device treatments for cancer and other conditions.